Holen Sie sich die Stockscreener-App
188.65
0.16%
-0.10
Schlusskurs vom Vortag:
$188.75
Offen:
$189.23
24-Stunden-Volumen:
670.14K
Relative Volume:
0.24
Marktkapitalisierung:
$40.07B
Einnahmen:
$742.00K
Nettoeinkommen (Verlust:
$-1.37B
KGV:
-26.67
EPS:
-7.0731
Netto-Cashflow:
$-1.07B
1W Leistung:
+1.23%
1M Leistung:
+11.01%
6M Leistung:
+60.21%
1J Leistung:
+406.33%
1-Tages-Spanne:
$185.89
$190.50
1-Wochen-Bereich:
$179.39
$193.53
52-Wochen-Spanne:
$34.00
$193.82
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
188.48 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
477.79 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.34 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
914.37 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.28 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-02-27 | Fortgesetzt | UBS | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines, Inc. (RVMD) stock price, news, quote and history - Yahoo Finance UK
Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid - simplywall.st
Revolution Medicines Inc. R (42Z.DU) Q4 FY2025 earnings call transcript - Yahoo Finance
Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th - GlobeNewswire Inc.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer - Zacks Investment Research
RVMD Maintains Rating by Wedbush -- Price Target Raised to $192.10 - GuruFocus
FDA panel confronting peptide controversy - STAT
symbol__ Stock Quote Price and Forecast - CNN
RVMD|Revolution Medicines Inc|Price:189.500|Chg%:+0.750 - TradingKey
Revolution Medicines (RVMD) Sees FDA Acceptance for Daraxonrasib Review - GuruFocus
Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA - Moomoo
Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA - TradingView
FDA accepts review of Revolution Medicines' dar... - Pluang
Oral Investigational Medicine for Pancreatic Cancer Is Accepted for FDA Review - Stock Titan
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(RVMD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
RVMD Maintained by Needham -- Price Target Raised to $236 - GuruFocus
Revolution Medicines, Inc. (RVMD) Stock Analysis: Why Analysts Are Bullish on This $39.58 Billion Biotech Innovator - DirectorsTalk Interviews
Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook? - simplywall.st
Why is Revolution Medicines (RVMD) up 9.3% since last earnings report? - MSN
Anti-Cancer Upstart’s Stock Surges 125% This Year as Billionaire Druckenmiller Builds Large Position - NAI500
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS) - Seeking Alpha
Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum - Quiver Quantitative
All eyes on data on Biogen’s tau therapy - STAT
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Titan with a Promising 7.17% Upside - DirectorsTalk Interviews
How Investors Are Reacting To Revolution Medicines (RVMD) Pancreatic Cancer Data For RAS G12D Inhibitor - simplywall.st
Truist reiterates Buy on Revolution stock, keeps $210 target By Investing.com - Investing.com India
Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating - Moomoo
Revolution Medicines Price Target Raised to $235.00/Share From $205.00 by Guggenheim - Moomoo
RVMD Maintained by Guggenheim -- Price Target Raised to $235 - GuruFocus
Revolution Medicines Is Maintained at Buy by Guggenheim - Moomoo
Better Growth Buy: Axsome vs Revolution Medicines - The Motley Fool
Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich? - simplywall.st
EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process - CancerNetwork
Drug that could extend lives of Canadians with pancreatic cancer remains out of reach for patients - The Globe and Mail
Revolution Medicines (RVMD) Holds Steady Near Resistance—Consolidation or Catalyst Ahead?Vol Target Rebalance - dars.gov.et
EMA speeds up review of Revolution Medicines' d... - Pluang
Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion - Quiver Quantitative
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process - The Manila Times
Revolution Medicines, Inc. - Via Ritzau
EMA fast-tracks Revolution Medicines' pancreatic cancer drug review - Stock Titan
Revolution Medicines wins EU fast track review for cancer drug - Seeking Alpha
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
Pulling the plug on cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma - Stockhouse
There's a Revolution in Cancer. But Can Big Pharma Afford It? -- Heard on the Street -- WSJ - Moomoo
Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com - Investing.com South Africa
RVMD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $195 - GuruFocus
Revolution Medicines stock hits all-time high at 193.12 USD - Investing.com
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Revolution Medicines Inc-Aktie (RVMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Director |
Jun 29 '26 |
Sale |
187.99 |
5,580 |
1,048,967 |
21,656 |
1.34%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):